Coherus BioSciences today announced positive topline results for the first of 3 pharmacokinetic bioequivalence studies comparing CHS-1420, an adalimumab biosimilar candidate, and European-sourced reference Humira.
Coherus BioSciences today announced positive topline results for the first of 3 pharmacokinetic bioequivalence studies comparing CHS-1420, an adalimumab biosimilar candidate, and European-sourced reference Humira.
The California-based biosimilar developer said that the study (a randomized, single-blind, single-dose, parallel-group study in 216 healthy subjects) met its 3 primary endpoints: maximum serum concentration, area under the time-concentration curve from first to last time point measured, and area under the time-concentration curve from first time point extrapolated to infinity. The 90% confidence intervals of the geometric mean ratios for all PK endpoints fell within predefined bioequivalence boundaries of 80% to 125%.
News of Coherus’ results comes just days after the FDA approved another adalimumab biosimilar, Boehringer Ingelheim’s (BI) Cyltezo, for multiple indications. BI is also currently investigating interchangeability between its product and Humira.
However, while AbbVie faces mounting competition for its top-selling treatment, it is unlikely that the drug maker will see immediate erosion of its sales in the US marketplace; earlier this month, AbbVie filed suit against BI, claiming that the biosimilar developer will infringe on 74 of its patents covering Humira. With only 8 of those patents currently being litigated, the case could take a substantial period of time and investment of resources to resolve.
Likewise, the first US-approved adalimumab biosimilar, Amgen’s Amjevita, is still awaiting its launch after receiving the FDA’s approval in September of 2016. Litigation in AbbVie v Amgen is ongoing, with the case recently reassigned to a visiting judge in the Eastern District of Pennsylvania.
AbbVie faces a harder fight to protect its Humira sales in the international marketplace, however. In Australia, a federal court recently ruled that AbbVie cannot file for an extension of 3 of its patents on Humira because they protect methods of use rather than the drug itself.
Meanwhile, Samsung Bioepis’ own adalimumab biosimilar, Imraldi, was approved in the European Union last week after having received a previous positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in June of 2017.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.